KPF
BDTX icon

K2 Principal Fund’s Black Diamond Therapeutics BDTX Stock Holding History

K2 Principal Fund’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,316
Closed -$21.4K – 229
2023
Q1 		$21.4K Sell
11,316
-146,876
-93% -$337K ﹤0.01% 209
2022
Q4 		$285K Sell
158,192
-873,319
-85% -$1.57M 0.04% 144
2022
Q3 		$1.74M Buy
1,031,511
+523,859
+103% +$1.62M 0.2% 104
2022
Q2 		$1.25M Buy
+507,652
New +$1.18M 0.14% 141

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

K2 Principal Fund's BDTX Position: Q2 2023 in Review

K2 Principal Fund sold out of Black Diamond Therapeutics (BDTX) in Q2 2023, closing a stake of 11,316 shares — an estimated $21.4K sold.

K2 Principal Fund first reported a position in BDTX in Q2 2022 and held it in 4 quarters. The position peaked at $1.74M in Q3 2022. 74 funds tracked by Wall St. Rank hold BDTX as of Q2 2023.

  • K2 Principal Fund reported no remaining Black Diamond Therapeutics position as of Q2 2023 after selling out during the quarter.
  • K2 Principal Fund sold 11,316 Black Diamond Therapeutics shares in Q2 2023, an estimated $21.4K.
  • K2 Principal Fund first reported a position in Black Diamond Therapeutics in Q2 2022 and held it in 4 quarters.
  • K2 Principal Fund's Black Diamond Therapeutics position peaked at $1.74M in Q3 2022.
  • 74 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2023.

Based on K2 Principal Fund's 13F filing for Q2 2023, filed 15 Aug 2023.